The chronic effects of Bacopa on cognitive performance in Alzheimer's patients - A pilot study

Phase 4

Withdrawn

• Conditions: Alzheimer's disease; Neurological - Alzheimer's disease; Alternative and Complementary Medicine - Other alternative and complementary medicine

• Registration Number: ACTRN12612000785808
• Lead Sponsor: Swinburne University of Technology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-07-24
• Last Update Posted: 4 May 2020

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Diagnosis of mild to moderate Alzheimer's disease
Aged 60 and above

Exclusion Criteria

less than 60 years of age
History of, or current psychiatric illness
Neurological diseases (other than Alzheimers)
Suffering from Endocrine, gastrointestinal or bleeding disorders
A history of chronic illness or infection
Pregnant or lactating
current use of medications including; anticoagulants, antidepressants, anti-psychotics, anxyolitics, anti-parkinsons.
current use of illicit drugs, cognitive enhancing drugs, or vitamin and herbal supplements

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive performance - score on the Alzheimer's Disease Assessment Scale- Cognition (ADAS-COG)[baseline and 90 days after intervention commencement];Cognitive performance - Mini Mental State Examination (MMSE) score[baseline and 90 days after intervention commencement];Performance on Cognitive Drug Research (CDR) computerised test battery[baseline and 90 days after intervention commencement]

Secondary Outcome Measures

Name	Time	Method
Mood, as measured by the Visual Analog Mood Sclaes (VAMS)[baseline and 90 days after intervention commencement];Quality of life, as measure by Cornell-Brown Scale for Quality of life in Dementia, and the Assessment of Quality of Life.[baseline, 30, 60 and 90 days after intervention commencement];Cognitive performance - Swinburne Computerised Cogntiive Assessment Battery (SUCCAB)[baseline and 90 days after intervention commencement];mean response time on an Inspection time task[baseline and 90 days after intervention commencement]